OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Bociek on the Clinical Uncertainty of MRD Negativity in CLL

April 6th 2021

R. Gregory Bociek, MD, discusses the clinical uncertainty of minimal residual disease negativity in chronic lymphocytic leukemia.

Dr. Ghidini on the Effects of Body Weight Loss in Gastric/GEJ Cancer

April 6th 2021

Michele Ghidini, MD, PhD, discusses the effects of body weight loss in gastric/gastroesophageal junction cancer.

Dr. Nakayama on Using Precision Medicine With Mirvetuximab Soravtansine in Ovarian Cancer

April 5th 2021

John Nakayama, MD, discusses the potential utility of precision medicine with mirvetuximab soravtansine in ovarian cancer.

Dr. Ghosh on the Potential Advantages of Frontline CAR T-Cell Therapy in DLBCL

April 5th 2021

Nilanjan Ghosh, MD, PhD, discusses the potential advantages of moving CAR T-cell therapy into the frontline setting for patients with diffuse large B-cell lymphoma.

Dr. Martin on the Safety Profile of Bispecific T-Cell Engagers in Multiple Myeloma

April 5th 2021

Thomas G. Martin, MD, discusses the safety profile of bispecific T-cell engagers in multiple myeloma.

Dr. Wagner on the Rationale for Immunotherapy in Angiosarcoma

April 5th 2021

Michael Wagner, MD, discusses the rationale for using immunotherapy in the treatment of patients with angiosarcoma.

Examining the Importance of the Institutional Perspectives in Cancer Webinars

April 2nd 2021

Jason Porter, MD, Subramanian Janakiraman, MD, Natalie S. Calendar, MD, Parameswaran Hari, MD, MRCP, and Kevin Kalinsky, MD, MS, discuss the importance of the Institutional Perspectives in Cancer webinars.

Dr. D’Angelo on the Potential Drawbacks of 5-Drug Combinations in B-Cell Lymphoma

April 2nd 2021

Christopher R. D’Angelo, MD, discusses the potential drawbacks of 5-drug combinations in B-cell lymphoma.

Dr. Meisel on the Nuances of Utilizing Adjuvant T-DM1 in HER2+ Breast Cancer

April 2nd 2021

Jane L. Meisel, MD, discusses some of the nuances of utilizing adjuvant ado-trastuzumab emtansine in HER2-positive breast cancer.

Dr. Miller on Approaching Frontline Maintenance Therapy in Ovarian Cancer

April 2nd 2021

Eirwen M. Miller, MD, discusses her approach to frontline maintenance therapy in ovarian cancer.

Dr. Shore on Future Research Directions with Darolutamide in Prostate Cancer

April 1st 2021

Neal D. Shore, MD, FACS, discusses future research directions with darolutamide for the treatment of patients with prostate cancer.

Dr. Wainberg on the Potential Role of Neoadjuvant Chemotherapy in Pancreatic Cancer

April 1st 2021

Zev A. Wainberg, MD, discusses the potential role of neoadjuvant chemotherapy in pancreatic cancer.

Dr. Eng on the Rising Incidence of Early-Onset CRC

April 1st 2021

Cathy Eng, MD, FACP, FASCO, discusses the rising incidence of early-onset colorectal cancer.

Dr. Kumar on the Evolving Role of Venetoclax in Relapsed/Refractory Multiple Myeloma

April 1st 2021

Shaji K. Kumar, MD, discusses the evolving role of venetoclax in relapsed/refractory multiple myeloma.

Dr. Ip on the Utility of Investigational Treatments for COVID-19 in Oncology

March 31st 2021

Andrew Ip, MD, MS, discusses the utility of investigational treatments for COVID-19 in patients with cancer.

Dr. Porter on Potential Sequencing With ADCs and TKIs in HER2+ Lung Cancer

March 31st 2021

Jason Porter, MD, discusses potential sequencing strategies with antibody-drug conjugates and TKIs in HER2-positive lung cancer.

Dr. Bazhenova on the Importance of Testing for HER2 Mutations in Lung Cancer

March 31st 2021

Lyudmila A. Bazhenova, MD, discusses the importance of testing for HER2 mutations in lung cancer.

Dr. Abu-Zeinah on the Efficacy of Interferon-Alpha in Polycythemia Vera

March 30th 2021

Ghaith Abu-Zeinah, MD, discusses the efficacy of interferon-alpha in polycythemia vera.

Dr. Kalinsky on the Potential Role of Ovarian Function Suppression in HR+/HER2- Breast Cancer

March 30th 2021

Kevin Kalinsky, MD, MS, discusses the potential role of ovarian function suppression in hormone receptor–positive, HER2-negative breast cancer.

Dr. Cohen on the Goals of the SPEARHEAD-2 Trial in Head and Neck Cancer

March 30th 2021

Ezra Cohen, MD, FRCPSC, FASCO, discusses the goals of the phase 2 SPEARHEAD-2 trial in head and neck cancer.